Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 30

  • Did you mean: tauler (288 items)

Nonorgan-specific autoantibodies in HIV-infected patients in the HAART era.

Iordache L, Bengoufa D, Taulera O, Rami A, Lascoux-Combe C, Day N, Parrinello M, Sellier PO, Molina JM, Mahr A.

Medicine (Baltimore). 2017 Mar;96(10):e6230. doi: 10.1097/MD.0000000000006230.


Infectious Zika virus in vaginal secretions from an HIV-infected woman, France, August 2016.

Penot P, Brichler S, Guilleminot J, Lascoux-Combe C, Taulera O, Gordien E, Leparc-Goffart I, Molina JM.

Euro Surveill. 2017 Jan 19;22(3). pii: 30444. doi: 10.2807/1560-7917.ES.2017.22.3.30444.


Tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients treated for tuberculosis: the ANRS 129 BKVIR trial.

Lortholary O, Roussillon C, Boucherie C, Padoin C, Chaix ML, Breton G, Rami A, Veziris N, Patey O, Caumes E, May T, Molina JM, Robert J, Tod M, Fagard C, Chêne G; ANRS 129 BKVIR Trial Group.

J Antimicrob Chemother. 2016 Mar;71(3):783-93. doi: 10.1093/jac/dkv384. Epub 2015 Dec 17.


Late Antiretroviral Therapy (ART) Initiation Is Associated with Long-Term Persistence of Systemic Inflammation and Metabolic Abnormalities.

Ghislain M, Bastard JP, Meyer L, Capeau J, Fellahi S, Gérard L, May T, Simon A, Vigouroux C, Goujard C; ANRS-COPANA Cohort Study Group.

PLoS One. 2015 Dec 4;10(12):e0144317. doi: 10.1371/journal.pone.0144317. eCollection 2015.


Is hardship during migration a determinant of HIV infection? Results from the ANRS PARCOURS study of sub-Saharan African migrants in France.

Desgrees-du-Lou A, Pannetier J, Ravalihasy A, Le Guen M, Gosselin A, Panjo H, Bajos N, Lydie N, Lert F, Dray-Spira R; PARCOURS Study Group.

AIDS. 2016 Feb 20;30(4):645-56. doi: 10.1097/QAD.0000000000000957.


Immunologic and Virologic Progression in HIV Controllers: The Role of Viral "Blips" and Immune Activation in the ANRS CO21 CODEX Study.

Noel N, Lerolle N, Lécuroux C, Goujard C, Venet A, Saez-Cirion A, Avettand-Fenoël V, Meyer L, Boufassa F, Lambotte O; ANRS C021 CODEX Study Group.

PLoS One. 2015 Jul 6;10(7):e0131922. doi: 10.1371/journal.pone.0131922. eCollection 2015.


Potential role for HIV-specific CD38-/HLA-DR+ CD8+ T cells in viral suppression and cytotoxicity in HIV controllers.

Hua S, Lécuroux C, Sáez-Cirión A, Pancino G, Girault I, Versmisse P, Boufassa F, Taulera O, Sinet M, Lambotte O, Venet A.

PLoS One. 2014 Jul 7;9(7):e101920. doi: 10.1371/journal.pone.0101920. eCollection 2014.


Blunted response to combination antiretroviral therapy in HIV elite controllers: an international HIV controller collaboration.

Boufassa F, Lechenadec J, Meyer L, Costagliola D, Hunt PW, Pereyra F, Deeks S, Pancino G, Taulera O, Lichterfeld M, Delobel P, Saez-Cirion A, Lambotte O; ANRS CO18 HIV Controllers Cohort; Cascade Collaboration in Eurocoord; SCOPE Cohort; International HIV Controllers Study.

PLoS One. 2014 Jan 17;9(1):e85516. doi: 10.1371/journal.pone.0085516. eCollection 2014.


Associations between 25-hydroxyvitamin D and immunologic, metabolic, inflammatory markers in treatment-naive HIV-infected persons: the ANRS CO9 «COPANA» cohort study.

Legeai C, Vigouroux C, Souberbielle JC, Bouchaud O, Boufassa F, Bastard JP, Carlier R, Capeau J, Goujard C, Meyer L, Viard JP; ANRS-COPANA Cohort Study Group.

PLoS One. 2013 Sep 18;8(9):e74868. doi: 10.1371/journal.pone.0074868. eCollection 2013.


Is clinical practice concordant with the changes in guidelines for antiretroviral therapy initiation during primary and chronic HIV-1 infection? The ANRS PRIMO and COPANA cohorts.

Krastinova E, Seng R, Yeni P, Viard JP, Vittecoq D, Lascoux-Combe C, Fourn E, Pahlavan G, Delfraissy JF, Goujard C, Meyer L; ANRS PRIMO and COPANA Cohorts.

PLoS One. 2013 Aug 1;8(8):e71473. doi: 10.1371/journal.pone.0071473. Print 2013. Erratum in: PLoS One. 2013;8(11). doi:10.1371/annotation/aed12a66-9c76-4e49-806b-881a2fe23bba. Goujard, Cecile [added].


Decreases in inflammatory and coagulation biomarkers levels in HIV-infected patients switching from enfuvirtide to raltegravir: ANRS 138 substudy.

Silva EF, Charreau I, Gourmel B, Mourah S, Kalidi I, Guillon B, De Castro N, Caron F, Braun J, Molina JM; ANRS 138 EASIER Study Group.

J Infect Dis. 2013 Sep;208(6):892-7. doi: 10.1093/infdis/jit280. Epub 2013 Jun 24.


Intensification of antiretroviral therapy through addition of enfuvirtide in naive HIV-1-infected patients with severe immunosuppression does not improve immunological response: results of a randomized multicenter trial (ANRS 130 Apollo).

Joly V, Fagard C, Grondin C, Descamps D, Yazdanpanah Y, Charpentier C, Colin de Verdiere N, Tabuteau S, Raffi F, Cabie A, Chene G, Yeni P; S 130 Apollo Trial Group.

Antimicrob Agents Chemother. 2013 Feb;57(2):758-65. doi: 10.1128/AAC.01662-12. Epub 2012 Nov 19.


Role and evolution of viral tropism in patients with advanced HIV disease receiving intensified initial regimen in the ANRS 130 APOLLO trial.

Charpentier C, Joly V, Larrouy L, Fagard C, Visseaux B, de Verdière NC, Raffi F, Yeni P, Descamps D; ANRS 130 APOLLO Trial Study Group.

J Antimicrob Chemother. 2013 Mar;68(3):690-6. doi: 10.1093/jac/dks455. Epub 2012 Nov 14.


Treatment for tuberculosis-associated immune reconstitution inflammatory syndrome in 34 HIV-infected patients.

Breton G, Bourgarit A, Pavy S, Bonnet D, Martinez V, Duval X, Longuet P, Abgrall S, Simon A, Leport C; Paradox-TB Study Group.

Int J Tuberc Lung Dis. 2012 Oct;16(10):1365-70. doi: 10.5588/ijtld.11.0693. Erratum in: Int J Tuberc Lung Dis. 2012 Dec;16(12):1712. ANRS-EP21 (Agence Nationale de Recherche sur le Sida) Paradox TB Study Group [corrected to Paradox-TB Study Group]. Int J Tuberc Lung Dis. 2014 Jun;18(6):754. Elmarsafy, S [corrected to El Marsafy, S].


Feasibility and acceptability of rapid HIV test screening (DEPIVIH) by French family physicians.

Gauthier R, Livrozet JM, Prevoteau du Clary F, Taulera O, Bouée S, Aubert JP, Py AM, Peter JM, Majerholc C, Héber Suffrin S, Compagnon C, Wajsbrot A.

Med Mal Infect. 2012 Nov;42(11):553-60. doi: 10.1016/j.medmal.2012.08.005. Epub 2012 Sep 29.


Acute microbiologically negative hypoxic interstitial pneumonia on HAART: Immune Reconstitution Inflammatory Syndrome unmasking Pneumocystis jiroveci infection with an atypical presentation.

Sovaila S, de Raigniac A, Picard C, Taulera O, Lascoux-Combe C, Sereni D, Bourgarit A.

J Med Life. 2012 Jun 12;5(2):189-91. Epub 2012 Jun 18.


Immune deficiency could be an early risk factor for altered insulin sensitivity in antiretroviral-naive HIV-1-infected patients: the ANRS COPANA cohort.

Boufassa F, Goujard C, Viard JP, Carlier R, Lefebvre B, Yeni P, Bouchaud O, Capeau J, Meyer L, Vigouroux C; ANRS COPANA Cohort Study Group.

Antivir Ther. 2012;17(1):91-100. doi: 10.3851/IMP1916.


Burden of HIV disease and comorbidities on the chances of maintaining employment in the era of sustained combined antiretoviral therapies use.

Dray-Spira R, Legeai C, Le Den M, Boué F, Lascoux-Combe C, Simon A, May T, Goujard C, Meyer L; ANRS-COPANA Cohort Study Group.

AIDS. 2012 Jan 14;26(2):207-15. doi: 10.1097/QAD.0b013e32834dcf61.


Residual HIV-1 RNA and HIV-1 DNA production in the genital tract reservoir of women treated with HAART: the prospective ANRS EP24 GYNODYN study.

Launay O, Tod M, Tschöpe I, Si-Mohamed A, Bélarbi L, Charpentier C, Goujard C, Taburet AM, Lortholary O, Leroy V, Bélec L; ANRS EP24 GYNODYN Study Group.

Antivir Ther. 2011;16(6):843-52. doi: 10.3851/IMP1856.


Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial.

Gallien S, Braun J, Delaugerre C, Charreau I, Reynes J, Jeanblanc F, Verdon R, de Truchis P, May T, Madelaine-Chambrin I, Aboulker JP, Molina JM; EASIER ANRS 138 Study Group.

J Antimicrob Chemother. 2011 Sep;66(9):2099-106. doi: 10.1093/jac/dkr269. Epub 2011 Jun 28.

  • Did you mean: tauler (288 items)

Supplemental Content

Loading ...
Support Center